Tadalafil Tablet
Product Images NDC 68071-3545

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-3545). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3545 3)

FDA Label Image

F35596a7-figure-01 (F35596a7 Figure 01)

FDA Label Image

F35596a7-figure-02 (F35596a7 Figure 02)

FDA Label Image

F35596a7-figure-03 (F35596a7 Figure 03)

FDA Label Image

F35596a7-figure-04 (F35596a7 Figure 04)

FDA Label Image

F35596a7-figure-05 (F35596a7 Figure 05)

FDA Label Image

F35596a7-figure-06 (F35596a7 Figure 06)

FDA Label Image

F35596a7-figure-07 (F35596a7 Figure 07)

This is a description of a study or clinical trial involving Tadalafil tablets at a dosage of 5 mg. The study included both a placebo group and a treatment group. The results indicated a significant difference between the two groups (p<0.01). The duration of treatment lasted for 12 weeks, with measurements taken at weeks 0, 1, 4, 8, and 12.*

FDA Label Image

F35596a7-figure-08 (F35596a7 Figure 08)

FDA Label Image

F35596a7-figure-09 (F35596a7 Figure 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.